Specific down‐regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes
- 6 June 2007
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 21 (12), 3355-3368
- https://doi.org/10.1096/fj.06-6713com
Abstract
Diabetic nephropathy (DN) remains a major complication in both type 1 and type 2 diabetes. Systemic administration of antitransforming growth factor-beta (TGF-beta) antibody has shown some promise in mouse models of DN. However, chronic blockade of the multifunctional TGB-beta could be problematic. Several downstream effects of TGF-beta are mediated by connective tissue growth factor (CTGF), which is up-regulated in several renal cells and secreted in the urine in the diabetic state. Using murine models of DN (type 1 and type 2) and a CTGF antisense oligonucleotide (ASO) of novel chimeric chemistry, we evaluated the specific role of this target in DN. In the type 1 model of DN, C57BL6 mice were made diabetic using streptozotocin injections and hyperglycemic animals were treated with CTGF ASOs (20 mg/kg/2 qw) for 4 months. ASO, but not mismatch control oligonucleotide, -treated animals showed significant reduction in target CTGF expression in the kidney with a concomitant decrease in proteinuria and albuminuria. Treatment with the CTGF ASO for 8 wk reduced serum creatinine and attenuated urinary albuminuria and proteinuria in diabetic db/db mice, a model of type 2 DN. The ASO also reduced expression of genes involved in matrix expansion such as fibronectin and collagen (I and IV) and an inhibitor of matrix degradation, PAI-1, in the renal cortex, contributing to significant reversal of mesangial expansion in both models of DN. Pathway analyses demonstrated that diabetes-induced phosphorylation of p38 MAPK and its downstream target CREB was also inhibited by the ASO. Our results strongly suggest that blocking CTGF using a chimeric ASO holds substantial promise for the treatment of DN.Keywords
Funding Information
- National Institutes of Health (RO1 DK58191)
This publication has 36 references indexed in Scilit:
- Pathogenesis of diabetic nephropathy: focus on transforming growth factor-β and connective tissue growth factorCurrent Opinion in Nephrology and Hypertension, 2001
- Transforming growth factor β contributes to progressive diabetic nephropathyProceedings of the National Academy of Sciences of the United States of America, 2000
- High Glucose Stimulates Proliferation and Collagen Type I Synthesis in Renal Cortical FibroblastsJournal of the American Society of Nephrology, 1999
- The CCN Family of Angiogenic Regulators: The Integrin ConnectionExperimental Cell Research, 1999
- The Connective Tissue Growth Factor/Cysteine- Rich 61/Nephroblastoma Overexpressed (CCN) FamilyEndocrine Reviews, 1999
- Transcriptional activation of transforming growth factor-β1 in mesangial cell culture by high glucose concentrationKidney International, 1998
- Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta.JCI Insight, 1994
- The modular architecture of a new family of growth regulators related to connective tissue growth factorFEBS Letters, 1993
- The glomerular mesangium in diabetes mellitusKidney International, 1993
- Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10.The Journal of cell biology, 1991